Boston Partners lifted its stake in shares of AstraZeneca Plc (NYSE:AZN – Free Report) by 31.3% during the third quarter, Holdings Channel.com reports. The firm owned 4,173,787 shares of the company’s stock after buying an additional 996,160 shares during the period. Boston Partners’ holdings in AstraZeneca were worth $673,408,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of the stock. Independent Advisor Alliance lifted its holdings in AstraZeneca by 30.1% during the 3rd quarter. Independent Advisor Alliance now owns 4,228 shares of the company’s stock worth $726,000 after buying an additional 978 shares in the last quarter. OneAscent Family Office LLC boosted its position in AstraZeneca by 61.9% in the 3rd quarter. OneAscent Family Office LLC now owns 4,179 shares of the company’s stock valued at $675,000 after buying an additional 1,598 shares during the last quarter. Composition Wealth LLC bought a new position in AstraZeneca in the 3rd quarter valued at $3,835,000. Cibc World Market Inc. boosted its position in AstraZeneca by 6.6% in the 3rd quarter. Cibc World Market Inc. now owns 52,168 shares of the company’s stock valued at $8,498,000 after buying an additional 3,244 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its stake in shares of AstraZeneca by 56.7% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 88,459 shares of the company’s stock valued at $14,283,000 after buying an additional 32,000 shares during the period. 20.35% of the stock is owned by institutional investors.
AstraZeneca Stock Down 1.9%
Shares of NYSE:AZN opened at $178.78 on Thursday. The company has a 50 day moving average price of $170.12 and a two-hundred day moving average price of $180.13. The company has a debt-to-equity ratio of 0.51, a quick ratio of 0.79 and a current ratio of 1.01. The company has a market capitalization of $277.28 billion, a PE ratio of 25.29, a PEG ratio of 1.41 and a beta of 0.24. AstraZeneca Plc has a 52 week low of $153.41 and a 52 week high of $212.71.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on the company. Zacks Research upgraded AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Royal Bank Of Canada assumed coverage on AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating on the stock. Citigroup reiterated a “buy” rating on shares of AstraZeneca in a research report on Tuesday, October 6th. Finally, Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Tuesday, September 15th. Sixteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $206.67.
View Our Latest Analysis on AstraZeneca
AstraZeneca Company Profile
AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.
Recommended Stories
- Five stocks we like better than AstraZeneca
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
